[go: up one dir, main page]

IS7491A - Benzoxazínon-afleidd efnasambönd, framleiðsla þeirra og notkun sem lyf - Google Patents

Benzoxazínon-afleidd efnasambönd, framleiðsla þeirra og notkun sem lyf

Info

Publication number
IS7491A
IS7491A IS7491A IS7491A IS7491A IS 7491 A IS7491 A IS 7491A IS 7491 A IS7491 A IS 7491A IS 7491 A IS7491 A IS 7491A IS 7491 A IS7491 A IS 7491A
Authority
IS
Iceland
Prior art keywords
benzoxazinone
drugs
preparation
derived compounds
derived
Prior art date
Application number
IS7491A
Other languages
English (en)
Inventor
Torrens Jover Antoni
Aurelio Castrillo Perez Jose
Frigola Constansa Jordi
Mas Prio Josep
Dordal Zueras Alberto
Angeles Fisas Escasany Maria
Original Assignee
Laboratorios Del Dr. Esteve S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Del Dr. Esteve S.A. filed Critical Laboratorios Del Dr. Esteve S.A.
Publication of IS7491A publication Critical patent/IS7491A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IS7491A 2002-04-09 2004-10-06 Benzoxazínon-afleidd efnasambönd, framleiðsla þeirra og notkun sem lyf IS7491A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200200813A ES2193875B2 (es) 2002-04-09 2002-04-09 Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
PCT/EP2003/003629 WO2003084952A1 (en) 2002-04-09 2003-04-08 Benzoxazinone-derived compounds, their preparation und use as medicaments

Publications (1)

Publication Number Publication Date
IS7491A true IS7491A (is) 2004-10-06

Family

ID=28686085

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7491A IS7491A (is) 2002-04-09 2004-10-06 Benzoxazínon-afleidd efnasambönd, framleiðsla þeirra og notkun sem lyf

Country Status (28)

Country Link
US (3) US7056914B2 (is)
EP (2) EP1497285B1 (is)
JP (1) JP2005529866A (is)
KR (1) KR20050008679A (is)
CN (1) CN1659164A (is)
AR (2) AR039256A1 (is)
AT (2) ATE489382T1 (is)
AU (2) AU2003222804A1 (is)
BR (1) BR0309083A (is)
CA (1) CA2481701A1 (is)
DE (2) DE60335094D1 (is)
DK (1) DK1500654T3 (is)
EC (1) ECSP045353A (is)
ES (3) ES2193875B2 (is)
HR (1) HRP20040919A2 (is)
IL (1) IL164442A0 (is)
IS (1) IS7491A (is)
MA (1) MA27692A1 (is)
MX (1) MXPA04009889A (is)
NO (1) NO20044322L (is)
NZ (1) NZ536167A (is)
PL (1) PL372537A1 (is)
PT (1) PT1500654E (is)
RU (1) RU2004133041A (is)
TN (1) TNSN04203A1 (is)
UA (1) UA79460C2 (is)
WO (2) WO2003084952A1 (is)
ZA (1) ZA200408275B (is)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
WO2005090340A1 (ja) * 2004-03-22 2005-09-29 Banyu Pharmaceutical Co., Ltd. ピペリジン－１－カルボキサミド誘導体
US8147853B2 (en) 2005-02-15 2012-04-03 The Procter & Gamble Company Personal care compositions containing hydrophobically modified non-platelet particles
EP1861066A2 (en) * 2005-03-21 2007-12-05 The Procter and Gamble Company Multi-phase personal care composition comprising visually distinct phases
US7820609B2 (en) 2005-04-13 2010-10-26 The Procter & Gamble Company Mild, structured, multi-phase personal cleansing compositions comprising density modifiers
WO2006113117A1 (en) * 2005-04-13 2006-10-26 The Procter & Gamble Company Mild, structured, multiphase personal cleansing compositions
ITMI20050909A1 (it) * 2005-05-19 2006-11-20 Acraf Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2-
US20120015009A9 (en) * 2005-06-07 2012-01-19 The Procter & Gamble Company Multi-phased personal care composition comprising a blooming perfume composition
ITMI20051523A1 (it) * 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
CN101326106A (zh) * 2005-12-08 2008-12-17 宝洁公司 包括邻近表面形貌定位的模内标签的容器
KR20080080155A (ko) * 2005-12-28 2008-09-02 니뽄 다바코 산교 가부시키가이샤 3,4-디히드로벤조옥사진 화합물 및 바닐로이드 수용체1형(ｖｒ１) 활성 저해제
US20070167338A1 (en) * 2006-01-09 2007-07-19 Mchugh Colin M Multiphase personal care compositions comprising beads
US8104616B2 (en) 2006-02-11 2012-01-31 The Procter & Gamble Company Clamshell package for holding and displaying consumer products
US8153144B2 (en) * 2006-02-28 2012-04-10 The Proctor & Gamble Company Stable multiphase composition comprising alkylamphoacetate
EP2061795B1 (en) * 2006-08-14 2014-01-15 Council of Scientific & Industrial Research Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
CL2007003044A1 (es) * 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
US20090028809A1 (en) * 2007-07-27 2009-01-29 Jonathan Robert Cetti Personal care article for sequentially dispensing compositions with variable concentrations of hydrophobic benefit materials
US20090028808A1 (en) * 2007-07-27 2009-01-29 The Procter & Gamble Company Personal care article for sequentially dispensing compositions with variable concentrations of partitioned benefit or suspended benefit agents
US20090029900A1 (en) * 2007-07-27 2009-01-29 The Procter & Gamble Company Personal care article for sequentially dispensing compositions with distinct fragrance characters
US7733945B2 (en) * 2008-03-18 2010-06-08 On-Ramp Wireless, Inc. Spread spectrum with doppler optimization
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
JP5642661B2 (ja) * 2009-03-05 2014-12-17 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
CN110684043B (zh) * 2019-08-13 2022-09-06 温州大学 一种c-n轴手性芳胺化合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216580T1 (de) * 1993-07-16 2002-05-15 Merck & Co Inc Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
WO1995028397A1 (en) 1994-04-14 1995-10-26 Merck & Co., Inc. Alpha1c adrenergic receptor antagonists
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
WO1997025992A1 (en) 1996-01-16 1997-07-24 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
WO1997038665A2 (en) 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998024768A1 (en) 1996-12-03 1998-06-11 Banyu Pharmaceutical Co., Ltd. Novel urea derivatives
JP2000510164A (ja) 1997-02-14 2000-08-08 バイエル・コーポレーシヨン 選択的神経ペプチドｙ受容体アンタゴニストとしてのアミド誘導体
WO1998040356A1 (en) 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
EP1119543B1 (en) 1998-10-07 2004-12-15 Ortho-McNeil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor
AU6000900A (en) 1999-07-23 2001-02-13 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
AU769081B2 (en) 1999-08-26 2004-01-15 Bristol-Myers Squibb Company NPY antagonists: spiroisoquinolinone derivatives
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
WO2002094825A1 (en) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Novel spiropiperidine derivative
EP1415986B1 (en) * 2001-08-07 2009-04-08 Banyu Pharmaceutical Co., Ltd. Spiro isobenzofuranes as neuropeptide y receptor antagonists
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
CA2481701A1 (en) 2003-10-16
US20040058920A1 (en) 2004-03-25
ES2193875B2 (es) 2005-03-01
PT1500654E (pt) 2006-06-30
US20040067941A1 (en) 2004-04-08
AR039256A1 (es) 2005-02-16
KR20050008679A (ko) 2005-01-21
EP1497285A1 (en) 2005-01-19
WO2003084952A1 (en) 2003-10-16
BR0309083A (pt) 2005-04-19
DE60303440T2 (de) 2006-10-26
EP1500654B1 (en) 2006-02-01
AR048567A1 (es) 2006-05-10
EP1500654A1 (en) 2005-01-26
DE60303440D1 (de) 2006-04-13
ZA200408275B (en) 2006-04-26
EP1497285B1 (en) 2010-11-24
PL372537A1 (en) 2005-07-25
US20060128701A1 (en) 2006-06-15
MA27692A1 (fr) 2006-01-02
WO2003084939A1 (es) 2003-10-16
ATE316966T1 (de) 2006-02-15
JP2005529866A (ja) 2005-10-06
AU2003216934A1 (en) 2003-10-20
ES2193875A1 (es) 2003-11-01
RU2004133041A (ru) 2005-09-10
DK1500654T3 (da) 2006-06-06
ES2356815T3 (es) 2011-04-13
HK1069820A1 (en) 2005-06-03
IL164442A0 (en) 2005-12-18
CN1659164A (zh) 2005-08-24
US7041665B2 (en) 2006-05-09
UA79460C2 (en) 2007-06-25
ES2258219T3 (es) 2006-08-16
NZ536167A (en) 2006-06-30
ECSP045353A (es) 2005-01-28
HRP20040919A2 (en) 2005-04-30
DE60335094D1 (de) 2011-01-05
US7514429B2 (en) 2009-04-07
TNSN04203A1 (en) 2007-03-12
AU2003222804A1 (en) 2003-10-20
MXPA04009889A (es) 2005-08-16
US7056914B2 (en) 2006-06-06
NO20044322L (no) 2004-10-12
ATE489382T1 (de) 2010-12-15

Similar Documents

Publication Publication Date Title
IS7491A (is) Benzoxazínon-afleidd efnasambönd, framleiðsla þeirra og notkun sem lyf
IS7946A (is) Lyf
FI7846U1 (fi) Farmaseuttinen valmiste, joka sisältää oksikodonia ja naloksonia
IL170758A0 (en) 7-amino-isoindolyl compounds and their pharmaceutical uses
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
DK1423376T3 (da) Bicyklisk forbindelse, fremstilling og anvendelse deraf
IL168102A0 (en) Chk-, pdk-and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
IL173195A0 (en) Cyclovinylazoline derivatives, their preparation and pharmaceutical compositions containing them
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
IS8422A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun þeirra
TWI319400B (en) Piperazinylacylpiperidine derivatives, their preparation and their therapeutic application
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
IL172733A0 (en) Diphenylpyridine derivatives, preparation and therapeutic application thereof
IS8219A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun
PL394604A1 (pl) Pochodna winyloazacykloalkanowa, jej zastosowanie oraz kompozycja farmaceutyczna
PT1525193E (pt) Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide
IS8220A (is) Bensímídasólafleiður, blöndur sem innihalda þær, framleiðsla þeirra og notkun
AU2003241671A8 (en) Controlled-release drug composition
HUP0401092A3 (en) 5-halogen-6-phenyl-7-fluoralkylamino-triazolopyrimidines as fungicides, preparation and use thereof
IL175245A0 (en) Thiozolidinones, production and use thereof as medicaments
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
TWI350287B (en) Acylaminothiazole derivatives, their preparation and their therapeutic application
EP1594440A4 (en) SELECTIVE AND SPECIFIC PREPARATION OF DISCRETE PEG COMPOUNDS
PL374761A1 (en) N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them